Compare Booking Holdings Inc (BKNG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booking Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Booking Holdings Inc trades at $212.74 (market cap $159.95B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Booking Holdings Inc pays a 0.79% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Booking Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BKNG | XBI | |
|---|---|---|
Market Cap | $159.95B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $228.83 | $164.28 |
52-Week Low | $154.13 | $86.92 |
Enterprise Value | $163.43B | — |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BKNG trades at $212.26, down 0.29% on the day, with a bullish technical signal from moving averages and strong support at $212. The company reported Q2 2026 EPS of $2.54, beating estimates, and revenue growth remains robust, though net income margin dipped to 20.07% in 2025. Analyst consensus is strongly bullish with a $239.31 price target, and recent news highlights resilient travel demand and AI integration efforts.
The outlook for BKNG is positive, driven by earnings beats and solid cash flow, but risks include geopolitical volatility and high debt levels. Upside potential exists if travel demand sustains and margins improve, yet investors face headwinds from competitive pressures and economic sensitivity.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Read more on BKNG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
